Therapeutic Drug Use in Women with Crohn's Disease and Birth Outcomes: a Danish Nationwide Cohort Study.
From: Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus C, Denmark.
The American journal of gastroenterology
- Publish Date: Jul 2007
- ISSN: 0002-9270
- Volume: 102
- Issue: 7
- Pages: 1406-13
- Medium: Print
- Language: English
- Citation (JAMA): Nørgård Bente, Pedersen Lars, Christensen Lisbet A, et al. Therapeutic Drug Use in Women with Crohn's Disease and Birth Outcomes: a Danish Nationwide Cohort Study.. Am. J. Gastroenterol. Jul 2007;102:1406-13
Abstract
BACKGROUND: Crohn’s disease (CD) is associated with increased risk of adverse birth outcomes. However, existing studies have not taken into account the impact of drug treatment. We examined the impact of drug treatment on birth outcomes — low birth weight (LBW), preterm birth, LBW at term, and congenital abnormalities (CAs) — among CD women. METHODS: A nationwide Danish cohort study of 900 children born to CD women between 1996 and 2004, based on the National Registry of Patients, the Birth Registry, and the nationwide prescription database. Pregnancies were classified according to receipt of prescriptions for CD medication: no drugs (reference group), 5-aminosalicylic acid (5-ASA)/sulfasalazine, steroids, and azathioprine (AZA)/6-mercaptopurine (6-MP). We used logistic regression analyses to estimate the relative risk of birth outcomes with 95% confidence intervals. We used a proxy measure for disease activity. RESULTS: Preterm births were more prevalent among steroid- and AZA/6-MP-exposed women (12.3% and 25%, respectively) compared with the reference group (6.5%). CAs were more prevalent among AZA/6-MP-exposed compared with reference group (15.4%vs 5.7%). Among steroid exposed, the risk of preterm birth was 1.4 (95% CI 0.6-3.3). Among AZA/6-MP exposed, the risk of preterm birth and CAs was 4.2 (95% CI 1.4-12.5) and 2.9 (95% CI 0.9-8.9), respectively. CONCLUSIONS: The relative risk of adverse birth outcomes among CD women varied by type of drugs prescribed during pregnancy. The risk of preterm birth and CAs was greater when AZA/6-MP was prescribed, even after adjusting for confounders. However, further information is needed to determine whether the associations are causal.
Mesh Headings (Keywords): 6-Mercaptopurine, Adolescent, Adult, Anti-Inflammatory Agents, Non-Steroidal, Confidence Intervals, Congenital Abnormalities, Crohn Disease, Denmark, Female, Follow-Up Studies, Glucocorticoids, Humans, Immunosuppressive Agents, Infant, Newborn, Male, Mesalamine, Population Surveillance, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Retrospective Studies, Risk Factors, Sulfasalazine
Check for Full Text / PubMed Unique Identifier (PMID): 17437503
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.